1M.D. Asistant Professor, Istanbul Medipol University, Department of Ophthalmology, Istanbul/TURKEY 2M.D., Istanbul Medipol University, Department of Ophthalmology, Istanbul/TURKEY 3M.D. Associate Professor, Istanbul Medipol University, Department of Ophthalmology, Istanbul/TURKEY 4M.D. Professor, Istanbul Medipol University, Department of Ophthalmology, Istanbul/TURKEY
Purpose: To investigate the effect of added low dose acetylsalicylic acid for the treatment and recurrence of central serous chorioretinopathy (CSCR).
Materials and Methods: The clinical data for 60 eyes of 60 patients with CSCR admitted to our clinic, between November 2010 and November
2013 were studied retrospectively. The demographic characteristics, best-corrected visual acuity and optical coherence tomography
central retinal thickness of all patients were recorded. Patients were divided into two groups according to their treatments; oral acetozolamide
and topical nepafenac 0.1% (Group A) and oral acetozolamide, topical nepafenac 0.1% plus low dose acetylsalicylic acid (Group B). The two
treatment groups were compared with age, sex, visual acuity, macular thickness and recurrence.
Results: At the first visit mean best-corrected visual acuity was 0.15±0.11 LogMAR and 0.18±0.13 LogMAR and in Group A and Group B,
respectively (p=0.43). The mean central retinal thickness at baseline was 406±61 mm and407±56 mm in Group A and Group B, respectively
(p=0.879). No statistically significant difference was found in visual acuity and macular thickness between the two groups at 1 week, 1., 3. or
6 months of medication. At the follow-up 12 patients (37%) in group A (n=32) and 4 patients (14%) in group B (n=28) had a second attack.
Conclusion: Although our results could not confirm a benefit of add the low dose acetylsalicylic acid to oral acetozolamide and topical nepefenac
0.1% therapy on visual acuity and macular thickness, but patients receiving acetylsalicylic acid had a lower recurrence rate in acute CSCR.
Acetylsalicylic acid, optical coherence tomography, central serous chorioretinopathy